10x Genomics, Inc. — Director's Dealing 2021

Dec 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-12-01

Reporting Person: STUELPNAGEL JOHN R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-01	Class A Common Stock	S	2000	$150.5108	Disposed	349616	Direct
2021-12-01	Class A Common Stock	S	1700	$151.0993	Disposed	347916	Direct
2021-12-01	Class A Common Stock	S	1100	$151.7932	Disposed	346816	Direct
2021-12-01	Class A Common Stock	S	100	$154.02	Disposed	346716	Direct
2021-12-01	Class A Common Stock	S	100	$155.55	Disposed	346616	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $151.00 to $151.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $151.53 to $152.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.